Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Perry who wrote (2226)	5/8/1998 4:13:00 AM
From: Anthony Wong	Respond to of 9523

Perry, he is talking about small caps, but he uses a model that analyses big caps as well as small caps and uses the RSRI as yardstick, coming to the conclusion that evaluation has beccome too high. He did say that small caps will correct more than large caps. My concern is: though he is not asking people to sell PFE, PFE's valuation is again in the spotlight (last week it was the Wall Street Journal which said that PFE's price is overextended). It was another Merrill Lynch analyst Steven C. Tighe who rated PFE a near-term ''buy'' on April 24. No target price given.